Fulcrum Free Cash Flow Per Share from 2010 to 2024
FULC Stock | USD 9.44 0.02 0.21% |
Free Cash Flow Per Share | First Reported 2010-12-31 | Previous Quarter (1.49) | Current Value (1.57) | Quarterly Volatility 0.47981743 |
Check Fulcrum Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Fulcrum main balance sheet or income statement drivers, such as Net Interest Income of 1.8 M, Interest Income of 1.8 M or Discontinued Operations of 0.0, as well as many exotic indicators such as Price To Sales Ratio of 155, Dividend Yield of 0.18 or Operating Cycle of 307. Fulcrum financial statements analysis is a perfect complement when working with Fulcrum Therapeutics Valuation or Volatility modules.
Fulcrum | Free Cash Flow Per Share |
Latest Fulcrum Therapeutics' Free Cash Flow Per Share Growth Pattern
Below is the plot of the Free Cash Flow Per Share of Fulcrum Therapeutics over the last few years. It is the amount of cash a company generates after accounting for capital expenditures, divided by the number of outstanding shares. It represents the cash available for dividends, share buybacks, or debt repayment per share. Fulcrum Therapeutics' Free Cash Flow Per Share historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Fulcrum Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Free Cash Flow Per Share | 10 Years Trend |
|
Free Cash Flow Per Share |
Timeline |
Fulcrum Free Cash Flow Per Share Regression Statistics
Arithmetic Mean | (2.08) | |
Coefficient Of Variation | (23.02) | |
Mean Deviation | 0.26 | |
Median | (2.01) | |
Standard Deviation | 0.48 | |
Sample Variance | 0.23 | |
Range | 2.1597 | |
R-Value | 0.02 | |
Mean Square Error | 0.25 | |
R-Squared | 0.0003 | |
Significance | 0.95 | |
Slope | 0 | |
Total Sum of Squares | 3.22 |
Fulcrum Free Cash Flow Per Share History
About Fulcrum Therapeutics Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Fulcrum Therapeutics income statement, its balance sheet, and the statement of cash flows. Fulcrum Therapeutics investors use historical funamental indicators, such as Fulcrum Therapeutics's Free Cash Flow Per Share, to determine how well the company is positioned to perform in the future. Although Fulcrum Therapeutics investors may use each financial statement separately, they are all related. The changes in Fulcrum Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Fulcrum Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Fulcrum Therapeutics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Fulcrum Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last Reported | Projected for 2024 | ||
Free Cash Flow Per Share | (1.49) | (1.57) |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out the analysis of Fulcrum Therapeutics Correlation against competitors. For information on how to trade Fulcrum Stock refer to our How to Trade Fulcrum Stock guide.You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Complementary Tools for Fulcrum Stock analysis
When running Fulcrum Therapeutics' price analysis, check to measure Fulcrum Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fulcrum Therapeutics is operating at the current time. Most of Fulcrum Therapeutics' value examination focuses on studying past and present price action to predict the probability of Fulcrum Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fulcrum Therapeutics' price. Additionally, you may evaluate how the addition of Fulcrum Therapeutics to your portfolios can decrease your overall portfolio volatility.
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Stocks Directory Find actively traded stocks across global markets |
Is Fulcrum Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fulcrum Therapeutics. If investors know Fulcrum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fulcrum Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.59) | Revenue Per Share 0.046 | Quarterly Revenue Growth 0.272 | Return On Assets (0.29) | Return On Equity (0.45) |
The market value of Fulcrum Therapeutics is measured differently than its book value, which is the value of Fulcrum that is recorded on the company's balance sheet. Investors also form their own opinion of Fulcrum Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Fulcrum Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fulcrum Therapeutics' market value can be influenced by many factors that don't directly affect Fulcrum Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fulcrum Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Fulcrum Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fulcrum Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.